Cidara Therapeutics Past Performance

How has Cidara Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CDTX is currently unprofitable.

Growing Profit Margin: CDTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CDTX is unprofitable, but has reduced losses over the past 5 years at a rate of 3.1% per year.

Accelerating Growth: Unable to compare CDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: CDTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies